New device performs better than old for removing blood clots

American Stroke Association late-breaking science - abstract 4436-LB 8

2012-02-06

(Press-News.org) An experimental blood clot-removing device outperformed the FDA-approved MERCI; retriever device, according to late-breaking science presented at the American Stroke Association's 2012 International Stroke Conference.

The SOLITAIRE; Flow Restoration Device is a self-expanding stent-based design that mechanically removes blood clots from blocked vessels after a stroke. After insertion into the clot using a thin tube, or catheter, the device traps the clot then both device and clot are removed, restoring blood flow. The MERCI retriever uses a tiny corkscrew, guided by a balloon-tipped wire, to snare and remove the blood clot.

In the Solitaire With the Intention for Thrombectomy (SWIFT) trial, the first U.S. clinical trial to compare the two devices, 113 stroke patients at 18 hospitals were randomly assigned to undergo clot removal with either device within eight hours of stroke onset between Feb. 2010-Feb. 2011.

The trial was ended at the suggestion of a safety monitoring committee nearly a year earlier than planned due to significantly better outcomes with the new device. The experimental device opened blocked vessels without causing symptomatic intracranial hemorrhage in 61 percent of patients. The currently approved device had the same result in 24 percent of cases - a statistically significant difference, said Jeffrey L. Saver, M.D., lead author of the study, professor of neurology and director of the Stroke Center in the Geffen School of Medicine at the University of California in Los Angeles.

The use of the new device also led to better survival three months after stroke. There was a 17.2 percent mortality rate with the new device versus 38.2 percent with the older one.

Stroke caused by a blood clot blocking a blood vessel supplying the brain is the most common type of stroke, accounting for about 87 percent of all strokes. The FDA-approved treatment for stroke with the most robust body of evidence is use of a clot-busting drug, but the drug must be given within 4.5 hours of symptom onset, and more quickly in older patients. When clot-busting drugs cannot be used or are ineffective, the clot can sometimes be mechanically removed, during or even after the 4.5 hours. The study didn't compare mechanical clot removal to drug treatment.

Although not yet approved in the United States, the new device is approved in Europe.

Other specific findings - all of which were statistically significant - were: Two percent of SOLITAIRE-treated patients had symptoms of bleeding in the brain compared to 11 percent of MERCI patients. At the 90-day follow-up, overall adverse event rates, including bleeding in the brain, were similar for the two devices. Fifty-eight percent of SOLITAIRE-treated patients had good mental/motor functioning at 90 days compared to 33 percent of MERCI patients. The SOLITAIRE device also opened more vessels when used as the first treatment approach, necessitating fewer subsequent attempts with other devices or drugs. Patients' average age was 67 years and 68 percent were male. Forty percent had not improved with standard clot-busting medication prior to the study, while the remainder had not received it.

The time from the start of symptoms to start of the clot retriever treatment was on average 4.9 hours for SOLITAIRE and 5.3 hours for MERCI. The study results account for this time difference.

"This heralds a new era in acute stroke care," said Saver. "We're going from our first generation of recanalization procedures, which were only moderately good in reopening target arteries, to now having a highly effective recanalization device. This really is a game-changing result."

### Co-authors are: Reza Jahan, M.D.; Elad Levy, M.D.; Tudor G. Jovin, M.D.; Blaise Baxter, M.D.; Raul Nogueira, M.D.; Wayne Clark, M.D.; Ronald Budzik, M.D.; Osama O. Zaidat, M.D, and the SWIFT Trial Investigators. Author disclosures are on the abstract. Covidien, the SOLITAIRE manufacturer, funded the study.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing science content. Revenues from pharmaceutical and device corporations are available at http://www.heart.org/corporatefunding.

NR12-1022 (ISC 2012/Saver)

(Note: Actual presentation is 12 p.m. CT, Friday, Feb. 3, 2012.)

Additional resources: Any downloadable video/audio interviews, B-roll, animation and images related to this news release are located on the right column of the release link located at http://www.newsroom.heart.org/pr/aha/_prv-new-device-performs-better-than-228372.aspx General ISC video and ISC photos available at http://www.newsroom.heart.org/ISC12-Video or newsroom.heart.org/ISC12-Photos. Follow news from ASA International Stroke Conference 2012 via Twitter: http://www.twitter.com/#!/heartnews. Follow #ASANews12.

ELSE PRESS RELEASES FROM THIS DATE:

Clopidogrel with aspirin doesn't prevent more small strokes, may increase risk of bleeding, death

2012-02-06

The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012. Because of these preliminary results, researchers ended the anti-clotting part of the Secondary Prevention of Small Subcortical Strokes Trial (SPS3) in August 2011. The part of the study that examines the effect of high blood pressure treatments ...

New drug doesn't improve disability among stroke patients

2012-02-06

A new drug that showed promise in animal studies and an early clinical trial didn't improve disability among stroke patients, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012. After a stroke and other types of brain damage, the brain naturally produces more granulocyte colony stimulating factor (G-CSF). The protein can prevent further cell injury by protecting nerve cells and boosting blood vessel growth. The new drug, AX200, is a manufactured form of G-CSF. Ninety days after treatment, patients ...

Vitamin D deficiency in geriatric patients

2012-02-06

The great majority of geriatric patients in a German rehabilitation hospital were found to have vitamin D deficiency. Stefan Schilling presents his study results in this week's issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2012; 109[3]: 33-8). In order to establish the vitamin D status in geriatric patients in Germany, the researchers measured 25-OH vitamin D in 1578 patients in the geriatric rehabilitation hospital in Trier after they had been examined on admission. Insufficiently high concentrations were found in 89% of patients, and 67% had severe ...

Rare mutations may help explain aneurysm in high-risk families

2012-02-06

An innovative approach to genome screening has provided clues about rare mutations that may make people susceptible to brain aneurysms, predisposing them to brain bleeds, according to preliminary late-breaking research presented at the American Stroke Association's International Stroke Conference 2012. For the first time, scientists applied a process called whole exome sequencing to seek gene mutations in families in which multiple relatives have intracranial aneurysms, a condition in which weakened, ballooned-out areas in arteries of the brain can rupture and cause a ...

Warfarin and aspirin are similar in heart failure treatment

2012-02-06

In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012. "Although there was a warfarin benefit for patients treated for four or more years, overall, warfarin and aspirin were similar," said Shunichi Homma, M.D., lead author of the study and the Margaret Milliken Hatch Professor of Medicine at Columbia University ...

Scientists chart high-precision map of Milky Way's magnetic fields

2012-02-06

Scientists at the Naval Research Laboratory (NRL) are part of an international team that has pooled their radio observations into a database, producing the highest precision map to date of the magnetic field within our own Milky Way galaxy. The team, led by the Max Planck Institute for Astrophysics (MPA), used the database they created and were able to apply information theory techniques to produce the map, explains NRL's Dr. Tracy Clarke, a member of the research team. "The key to applying these new techniques is that this project brings together over 30 researchers ...

A new study shows how to boost the power of pain relief, without drugs

2012-02-06

Placebos reduce pain by creating an expectation of relief. Distraction—say, doing a puzzle—relieves it by keeping the brain busy. But do they use the same brain processes? Neuromaging suggests they do. When applying a placebo, scientists see activity in the dorsolateral prefrontal cortex. That's the part of the brain that controls high-level cognitive functions like working memory and attention—which is what you use to do that distracting puzzle. Now a new study challenges the theory that the placebo effect is a high-level cognitive function. The authors—Jason T. Buhle, ...

Schooling protects fleeing children from disease

2012-02-06

Refugee children have scant access to medical care and are particularly vulnerable to disease. Fresh research results from the University of Copenhagen show that just a few hours of schooling a week may have a pronounced positive impact on their health not only in childhood but later in life when they achieve adulthood. "There is an unambiguous link between health and schooling among refugee groups as they flee," says external Associate Professor Tania Dræbel, PhD from the Department of Public Health, University of Copenhagen, where she works as an expert in health among ...

The complex relationship between memory and silence

2012-02-06

People who suffer a traumatic experience often don't talk about it, and many forget it over time. But not talking about something doesn't always mean you'll forget it; if you try to force yourself not to think about white bears, soon you'll be imagining polar bears doing the polka. A group of psychological scientists explore the relationship between silence and memories in a new paper published in Perspectives on Psychological Science, a journal of the Association for Psychological Science. "There's this idea, with silence, that if we don't talk about something, it starts ...

UC San Diego Moores Cancer Center offers new hope for deadly brain tumor

2012-02-06

Jim Black is fighting the meanest, most aggressive, most common kind of brain tumor in the United States: recurrent glioblastoma multiforme (GBM). In the United States, each year, approximately 10,000 patients are affected by GBM. Now, a novel investigational device – available only at clinical trial sites – is offering new hope to these patients. The non-invasive procedure – called Tumor Treating Fields (TTF) – is delivered using a portable device – called the NovoTTF-100A System made by Novocure. The TTF procedure uses alternating electrical fields to disrupt the ...

New device performs better than old for removing blood clots

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: